The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.

The rate of maternal mortality related to cardiovascular causes more than doubled between 1999 and 2022 in the United States, ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...

One study found that Black women were 3 times more likely to die of maternal deaths due to cardiovascular disease than White ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease. Earlier in ...

Patients with MASLD had nearly twice the all-cause mortality rate as the general population, suggesting the need for multidisciplinary care to reduce excess mortality, researchers said.